Fulcrum Therapeutics
Tracked across 4 events · 38 articles · First seen May 12, 2026 · Last active Aug 31, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Fulcrum Therapeutics stock plunged 50% due to FDA safety concerns regarding its lead drug candidate, pociredir, leading to its discontinuation and a strategic review. The company is now under investigation for potential securities fraud.
Jun 02, 2026 · 6 articles
Business
Impact: Fulcrum is merging with Slate Medicines in an all-stock deal, contributing net cash and paying a large dividend to shareholders. The merger provides a path forward after discontinuing pociredir, with Fulcrum shareholders receiving about 5% of the combined company.
Aug 17, 2026 · 6 articles
Regulatory
Kaplan Fox & Kilsheimer is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (Nasdaq: FULC). The investigation stems from Fulcrum's June 1, 2026 announcement that it was discontinuing its pociredir program for sickle cell…
Impact: Fulcrum Therapeutics is the subject of the investigation. The discontinuation of its pociredir program and the subsequent stock price decline have severely impacted the company's market value and future prospects. The investigation adds further legal and financial risk.
Jul 15, 2026 · 20 articles
90
United States — Food and Drug Administration concluded malignancy risk Fulcrum TherapeuticsFulcrum Therapeutics...
88
Fulcrum Therapeutics discontinued drug programFulcrum Therapeutics...
30
Kaplan Fox & Kilsheimer investigating securities violations Fulcrum TherapeuticsFulcrum Therapeutics...
ERGEN INTELLIGENCE
Track Fulcrum Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard